US-based based contract development and manufacturing organisation (CDMO) Alcami Corporation announced on Tuesday the GMP readiness of a third sterile fill-finish line at its Research Triangle Park, North Carolina campus.

This is the fifth sterile fill-finish line that is qualified for GMP clinical and commercial manufacturing within Alcami's drug product manufacturing network. The newest line includes an automated grade A isolator fill line, designed to deliver filling, stoppering, and capping under aseptic conditions. It supports a wide range of vial formats, from 2R to 30R and available for liquid and lyophilisation products.

Alcami said that these enhancements enable the company to further meet the evolving needs of its clients. From early-stage clinical development to full-scale commercial production in vials and pre-filled syringes, Alcami is positioned to support a wide range of small and large molecule programmes.